Aileron Therapeutics Inc

+0.06 (+2.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Aileron Therapeutics Inc Stock, NASDAQ:ALRN

285 Summer Street, Unit 101, Boston, Massachusetts 02210
United States of America
Phone: +1.617.995.0900
Number of Employees: 9


Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engaged in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.